Tocqueville Asset Management L.P. Grows Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Tocqueville Asset Management L.P. boosted its stake in Thermo Fisher Scientific by 6.3% in Q1, owning 80,473 shares valued at $40 million.
• Thermo Fisher reported a quarterly EPS of $5.36, exceeding estimates, with a revenue of $10.86 billion for the quarter.
• The company announced a quarterly dividend of $0.43 per share, with a yield of 0.4%, slated for payment on October 15th.

Tocqueville Asset Management L.P. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 80,473 shares of the medical research company's stock after purchasing an additional 4,790 shares during the period. Tocqueville Asset Management L.P.'s holdings in Thermo Fisher Scientific were worth $40,043,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of TMO. Bernard Wealth Management Corp. acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth $25,000. Ameriflex Group Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth $30,000. IMA Advisory Services Inc. bought a new position in shares of Thermo Fisher Scientific during the first quarter worth $35,000. Navigoe LLC bought a new stake in Thermo Fisher Scientific during the 4th quarter worth about $37,000. Finally, Smallwood Wealth Investment Management LLC bought a new stake in Thermo Fisher Scientific during the 1st quarter worth about $37,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $52,037,916.68. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,400 shares of company stock valued at $8,345,792. 0.33% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have commented on TMO. Raymond James Financial reissued an "outperform" rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Royal Bank Of Canada lowered their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Evercore ISI lowered their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, Robert W. Baird increased their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Stock Down 1.2%

NYSE:TMO traded down $6.1430 during trading hours on Thursday, reaching $488.6670. The company had a trading volume of 594,246 shares, compared to its average volume of 2,483,777. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The firm has a market cap of $184.53 billion, a price-to-earnings ratio of 28.28, a P/E/G ratio of 2.66 and a beta of 0.74. The business's 50-day simple moving average is $439.69 and its two-hundred day simple moving average is $458.78. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the firm earned $5.37 earnings per share. The business's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.